Additional pathway-informed candidate therapeutics targeting molecular mediators of the COVID-19 hyperinflammatory response include biologics such as TNF-α inhibitors, IL-6 inhibitors, tamoxifen-mediated inhibition of Eomes, IL-17 inhibitors, CDK inhibition, exogenous delivery of soluble FcγRIIB, and JAK inhibitors. Here, IL6 is linked to COVID-19.